1 day Ago By Defense World Staff
Renaissance Technologies LLC lifted its position in biote Corp. ( NASDAQ:BTMD – Free Report ) by 9.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The institutional investor owned 178,994 shares of the company’s stock after purchasing an additional 16,017 shares during the period. Renaissance Technologies LLC owned about 0.33% of biote worth $1,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of BTMD. Commonwealth Equity Services LLC purchased a new stake in biote in the 4th quarter worth $68,000. Intech Investment Management LLC purchased a new stake in shares of biote during the fourth quarter worth about $71,000.
SG Americas Securities LLC bought a new stake in biote during the 4th quarter valued at approximately $76,000. Thompson Davis & CO. Inc.
purchased a new position in biote in the 4th quarter worth approximately $77,000. Finally, Wells Fargo & Company MN boosted its stake in biote by 49.9% in the 4th quarter.
Wells Fargo & Company MN now owns 12,742 shares of the company’s stock worth $79,000 after purchasing an additional 4,243 shares during the period. 21.68% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Separately, Craig Hallum reduced their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.
biote Stock Up 2.0 % Shares of BTMD stock opened at $3.54 on Wednesday.
The stock has a market cap of $193.67 million, a P/E ratio of 13.62 and a beta of 1.
17. The company’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $5.
03. biote Corp. has a 52 week low of $3.
04 and a 52 week high of $8.44. Insider Buying and Selling In related news, Director Stephen Mark Cone purchased 38,104 shares of the company’s stock in a transaction that occurred on Monday, March 17th.
The stock was bought at an average price of $3.88 per share, for a total transaction of $147,843.52.
Following the completion of the transaction, the director now owns 160,829 shares in the company, valued at approximately $624,016.52. The trade was a 31.
05 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website . Also, major shareholder Guines Llc acquired 8,801 shares of the firm’s stock in a transaction on Monday, April 21st.
The shares were bought at an average price of $3.27 per share, for a total transaction of $28,779.27.
Following the completion of the transaction, the insider now owns 4,173,101 shares of the company’s stock, valued at approximately $13,646,040.27. This trade represents a 0.
21 % increase in their ownership of the stock. The disclosure for this purchase can be found here . Over the last three months, insiders have bought 974,110 shares of company stock worth $3,170,331.
Corporate insiders own 24.00% of the company’s stock. biote Profile ( Free Report ) biote Corp.
operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Featured Articles Five stocks we like better than biote Investing In Preferred Stock vs. Common Stock Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet How to Capture the Benefits of Dividend Increases Coca-Cola Company Stock Can Bubble to New Highs This Year How to Evaluate a Stock Before Buying 3 Stocks Lifting 2025 Guidance Despite Market Jitters Want to see what other hedge funds are holding BTMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for biote Corp.
( NASDAQ:BTMD – Free Report ). Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter .
.
